Alkermes PLC
Închisă
SectorSănătate
50.18 4.32
Rezumat
Modificarea prețului
24h
Minim
47.88
Maxim
51.57
Venit | -116M -66M |
|---|---|
Vânzări | 8.4M 393M |
P/E Medie Sector | 51.133 50.958 |
EPS | 0.38 |
Marjă de profit | -16.92 |
Angajați | 2,050 |
EBITDA | -98M -22M |
Recomandări | Puternic Cumpărare |
|---|---|
Prognoză pe 12 luni | +4.01% upside |
Următoarele câștiguri | 28 iul. 2026 |
|---|
Capitalizare de piață | 2B 7.7B |
|---|---|
Deschiderea anterioară | 45.86 |
Închiderea anterioară | 50.18 |
Sentimentul știrilor
By Acuity
10%
90%
13 / 342 Clasament în Healthcare
Alkermes PLC Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Despre Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
